GlassScriptPhysician profile
Melvin B Weiss
NPI 1306849179
$6,423.01
in general payments reported to CMS, 2019-2025
22 companies · $151 in 2025
The $151 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,617 · 2020: $551 · 2021: $1,515 · 2022: $896 · 2023: $440 · 2024: $252 · 2025: $151.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $843.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $843.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,560.80 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $814.55 | 2019-2024 | Jardiance |
| Janssen Pharmaceuticals, INC | $687.58 | 2019-2023 | Xarelto |
| Abbott Laboratories | $602.57 | 2020-2025 | Jot Dx |
| Astrazeneca Pharmaceuticals LP | $508.01 | 2020-2023 | Farxiga |
| Novartis Pharmaceuticals Corporation | $383.65 | 2019 | |
| Amgen INC. | $260.96 | 2019 | |
| Biotronik INC. | $259.30 | 2019-2021 | |
| Novo Nordisk INC | $250.00 | 2021-2022 | |
| Amarin Pharma, INC. | $171.72 | 2019-2020 | |
| Actelion Pharmaceuticals US, INC. | $161.68 | 2019 | |
| Janssen Scientific Affairs, LLC | $136.72 | 2023 | Xarelto |
| Daiichi Sankyo INC. | $125.00 | 2019 | |
| Pfizer INC. | $123.75 | 2020 | |
| Portola Pharmaceuticals, LLC | $115.64 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $78.82 | 2019 | |
| Medtronic, INC. | $68.26 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $29.25 | 2019 | |
| Edwards Lifesciences Corporation | $24.57 | 2019 | |
| Alnylam Pharmaceuticals INC. | $22.98 | 2019 | |
| Lundbeck LLC | $21.88 | 2019 | |
| Gilead Sciences, INC. | $15.32 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melvin Weiss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.